Albemarle (NYSE:ALB) received mixed analyst ratings with 6 somewhat bullish, 6 indifferent, and 1 somewhat bearish. The average 12-month price target is now $168.85, down from $213.92, with a high estimate of $308.00 and a low of $128.00. Analysts from firms including TD Cowen, Mizuho, Oppenheimer, UBS, Deutsche Bank, Keybanc, B of A Securities, Piper Sandler, BMO Capital, and RBC Capital have adjusted their ratings and price targets. Albemarle's financial performance shows strong market recognition, revenue growth, profitability, and effective asset utilization, with a market cap above industry averages, a revenue growth rate of 10.46%, a net margin of 13.09%, an ROE of 3.07%, an ROA of 1.59%, and a healthy debt-to-equity ratio of 0.37.